Methods for killing tumor and tumor associated endothelial cells using adenoviral mutants
CA 2348634 A1 · Owner: Williams, Angelica · Inventors: Heise, Carla; Propst, Meisa; Sampson-Johannes, Adam
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods and compositions for substantially and selectively ablating cancer cells and dividing endothelial cells while substantially sparing quiescent normal cells are described consisting of replication competent adenoviral mutants that are mutant in E1A RB family member binding site region of the virus, and preferably in the E1A-CR2 region which mutants show superior , replication and efficacy compared to wild-type adenovirus in multiple tumor cell lines and in proliferating microvascular endothelial cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 15, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 15, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 15, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.